Oragenics Soars 11.11% on $20M Capital Raise for Clinical Trials

Oragenics' stock surged 11.11% in pre-market trading on July 3, 2025, driven by a significant capital raise initiative.

Oragenics has announced a $20 million preferred stock offering, aiming to sell up to 800,000 shares of Series H convertible preferred stock along with accompanying warrants. This move is part of the company's strategy to secure funding for its ongoing clinical trials and research and development activities, particularly for its neurosteroid ONP-2, designed to treat concussions.

The proceeds from this offering will also be used to repay a $3 million bridge note and to support working capital and other general corporate purposes. The offering is expected to close on July 2, with Dawson James Securities, Inc. acting as the sole placement agent.

This capital raise is a strategic move by Oragenics to bolster its financial position, enabling the company to continue its innovative work in the biotechnology sector, particularly in the areas of neurology and infectious diseases. The funds will support the development of drug candidates for treating mild traumatic brain injury and other related research initiatives.